Innovations Abound - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovations Abound

Pharmaceutical Technology

Here's a look at some of the most interesting and thematic responses you—our readers—provided for Pharmaceutical Technology's anniversary survey of industry advances and directions.

Which events significantly affected or caused changes in pharmaceutical manufacturing?
"My graduation from college."

"Better chemistry," "gene technology," and "train(ing) dogs to sniff counterfeit drugs" will impact the future direction of pharmaceutical manufacturing.

The rationalization of small-molecule manufacturing facilities in APIs.
"Is the leading edge of pharma."

On the use of information technology:
"There is no replacement for an advanced and validated computerized system."

When it comes to formulation development and manufacturing practices.
"The advice from our management is to have 50% of our workload outsourced—and especially routine work."

Thanks to advanced analytical technologies in NIR.
"(we) don't actually need to prepare the sample tediously."

With regard to the GMPs for the 21st century.
"It's been a long time since 1978, and it is time to update."

"...Most companies have found a way around..."
21 CFR Part 11 regulation.

ADVERTISEMENT

RELATED CONTENT
Innovations Abound
Signature Authentication Can Restore Confidence
ExcipientFest Attendees Discuss Regulatory and Quality Concerns
Acceptable Analytical Practices for Justification of Specifications
Qualification, Validation, and Verification
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here